Type 2 helper T cell cytokine production (Th2 cytokine production)

Type 2 helper T cell (Th2) cytokine production is a coordinated biological process involving the synthesis and secretion of a specific subset of cytokines, most notably Interleukin-4 (IL-4), Interleukin-5 (IL-5), and Interleukin-13 (IL-13) (Wynn, 2003, Nature Reviews Immunology). This process is initiated when naive CD4+ T cells are activated in the presence of IL-4, leading to the expression of the master transcription factor GATA3, which orchestrates the Th2 phenotype (Galli et al., 2008, Nature). Biologically, Th2 cytokine production is essential for the adaptive immune response against helminth parasites and for promoting B cell isotype switching to IgE. However, the chronic overproduction of these cytokines is a primary driver of 'Type 2 inflammation,' which underlies the pathophysiology of allergic diseases such as atopic asthma, atopic dermatitis, and chronic rhinosinusitis (Gandhi et al., 2016, Nature Reviews Drug Discovery). Therapeutic agents like Dupilumab and Mepolizumab work by inhibiting these cytokines or their receptors, thereby reducing eosinophil recruitment and mucus production (FDA, 2021). Because this process is a pathway rather than a single molecular entity, it is considered a biological process that encompasses multiple individual therapeutic targets.

Other names

Th2 responseType 2 immune responseTh2 cytokine synthesisT-helper cell type 2 cytokine productionGO:0032643

Inhibition of specific Th2-associated cytokines (IL-4, IL-5, IL-13) or their receptors (IL-4Ra, IL-5Ra), or upstream alarmins like TSLP, to interrupt the signaling cascade that leads to type 2 inflammation (Gandhi et al., 2016, Nature Reviews Drug Discovery).